Description
Depogeston 50 mg/ ml solution for injection for dogs and cats
Statement of the active substance(s) and other ingredient(s)
Active substance:
Medroxyprogesterone acetate – 50 mg/ml
Excipients:
Methyl parahydroxybenzoate – 1.2 mg/ml
Propyl parahydroxybenzoate – 0.2 mg/ml
White suspension with sediment at the bottom, homogeneous after shaking.
Target species
Dog, cat.
Indications for use
Prevention of oestrus in bitches and queens.
Treatment of nymphomania in queens, not related to ovarian cysts.
Contraindications
Do not use:
– in the proestrus, oestrus, metoestrus phase,
– during pregnancy and lactation,
– in case of diagnosed mammary gland cancer,
– in juvenile and growing animals,
– do not use before the first heat,
– in animals with diabetes,
– in inflammations of the reproductive system,
– in whippet/greyhound bitches,- in case of known sensitivity to the active substance or any of the excipients.
Special warnings
Special warnings:
Before product administration, it is recommended to conduct relevant laboratory tests to determine the phase in the oestrus cycle.
Special precautions for safe use in the target species:
The first dose of the product should be administered not earlier than 2 weeks after parturition and not later than 1 month prior to the expected heat.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Pregnant women and women of childbearing potential should avoid contact with the product. In case of accidental spillage onto skin or eye contact, flush the contaminated site with water. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Pregnancy:
Do not use during pregnancy.
Lactation:
Do not use during lactation. Administration of the product during lactation reduces production of milk by the mammary gland due to inhibited gonadotropin secretion by the pituitary gland.
Interaction with other medicinal products and other forms of interaction:
Administration of gonadotropins (LH, FSH) and estrogens to restore the oestrus cycle following product use may increase the risk of pathological lesions in the endometrium.
Overdose:
Overdosing the product may cause transient changes in animal temperament, increased appetite, induce lactation. Adverse events likely to occur after long-term use of the product have been described in item 6.
Major incompatibilities:
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
Adverse events
Target species: dog, cat.
| Rare (1 to 10 animals/10 000 animals treated): | Hyperpigmentation or skin and hair discolouration1 |
| Frequency unknown (cannot be determined based on the available data): | Pyometra2,3, proliferative endometrium3, cystic endometrial hyperplasia3, ovarian cysts3, acromegaly3, mammary gland cancer3. Inhibited adrenal function, diabetes, Changes in animal temperament4, increased appetite |
1 May occur at the injection site.
2 May occur in bitches.
3 Administration of medroxyprogesterone for more than 2 years is conducive to the development of diseases of the uterus and mammary gland.
4 Is of transient nature.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorization holder using the contact details found at the end of this leaflet, or via your national reporting system:
Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Al. Jerozolimskie 181C
PL 02-222 Warsaw
Tel.: +48 22 49 21 687
Fax: +48 22 49 21 605
E-mail: pw@urpl.gov.pl
Website: https://smz.ezdrowie.gov.pl
Dosage for each target species, route(s) and method(s) of administration
Subcutaneous or intramuscular use in the following doses:
bitches: 50 – 100 mg of medroxyprogesterone acetate per animal subcutaneously or intravenously: i.e.
– small animals (less than 10 kg b.w.) – 1.0 ml of the product per animal;
– medium-sized (10-25 kg b.w.) – 1.5 ml of the product per animal;
– large (25-45 kg b.w.) – 2.0 ml of the product per animal;
queens: 50 mg of medroxyprogesterone acetate per animal subcutaneously, i.e. 1.0 ml of the product per animal.
The first dose of the product should be administered not earlier than 2 weeks after parturition and not later than 1 month prior to the expected heat.
In order to permanently block the cycle, administer the product regularly in bitches every 5 months in bitches and every 3 to 4 months in queens, however for no longer than 2 years. Animal owners should be made aware that the onset of the first heat following the use of the product depends on animal’s specific characteristics and it usually occurs after 5 to 6 months in bitches and 3 to 4 months in queens, although this may be longer in some instances.
Advice on correct administration
Shake before use to obtain a homogeneous suspension.
Withdrawal period(s)
Not applicable
Special precautions for storage
Keep out of the sight and reach of children.
Store below 25°C. Do not freeze.
Do not use this veterinary medicinal product after the expiry date which is stated on the label. The expiry date refers to the last day of that month.
Shelf-life after first opening the immediate packaging: 28 days.
Special precautions for disposal
Medicines should not be disposed of via wastewater or household waste.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.
Ask your veterinary surgeon how to dispose of medicines no longer required.
Classification of veterinary medicinal products
Veterinary medicinal product subject to a veterinary prescription
Marketing authorisation numbers and pack sizes
MA number: 978/00
Pack sizes: 6 ml
Date on which the package leaflet was last revised
18/06/2025
Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).
Contact details
Marketing authorisation holder and manufacturer responsible for batch release:
Biowet Puławy Sp. z o.o.
Henryka Arciucha 2
24-100 Puławy
Poland
Tel./Fax: + 48 (81) 886 33 53, Tel: + 48 (81) 888 91 00
e-mail: sekretariat@biowet.pl
Contact details to report suspected adverse events:
Biowet Puławy Sp. z o.o.
Henryka Arciucha 2
24-100 Puławy
Poland
Tel.: + 48 (81) 888 91 33, Tel: +48 509 750 444
e-mail: biowet@biowet.pl
SPC: 2025-06-18
2025-07-17
